You just read:

Kleo Pharmaceuticals Announces a CD38 Targeting Antibody Recruiting Molecule (ARM™) to Treat Multiple Myeloma as the First Clinical Candidate in its Partnership with PeptiDream

News provided by

Kleo Pharmaceuticals, Inc.

Jun 18, 2019, 07:35 ET